Cargando…

Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia

BACKGROUND: Stroke is one of the leading causes of death worldwide and a major cause of morbidity and mortality in the United States of America. Brain ischemia-reperfusion (IR) triggers a complex series of biochemical events including inflammation. Leukotrienes derived from 5-lipoxygenase (5-LOX) ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Jatana, Manu, Giri, Shailendra, Ansari, Mubeen A, Elango, Chinnasamy, Singh, Avtar K, Singh, Inderjit, Khan, Mushfiquddin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526713/
https://www.ncbi.nlm.nih.gov/pubmed/16689995
http://dx.doi.org/10.1186/1742-2094-3-12
_version_ 1782128934325846016
author Jatana, Manu
Giri, Shailendra
Ansari, Mubeen A
Elango, Chinnasamy
Singh, Avtar K
Singh, Inderjit
Khan, Mushfiquddin
author_facet Jatana, Manu
Giri, Shailendra
Ansari, Mubeen A
Elango, Chinnasamy
Singh, Avtar K
Singh, Inderjit
Khan, Mushfiquddin
author_sort Jatana, Manu
collection PubMed
description BACKGROUND: Stroke is one of the leading causes of death worldwide and a major cause of morbidity and mortality in the United States of America. Brain ischemia-reperfusion (IR) triggers a complex series of biochemical events including inflammation. Leukotrienes derived from 5-lipoxygenase (5-LOX) cause inflammation and are thus involved in the pathobiology of stroke injury. METHODS: To test the neuroprotective efficacy of 5-LOX inhibition in a rat model of focal cerebral IR, ischemic animals were either pre- or post-treated with a potent selective 5-LOX inhibitor, (N- [3-[3-(-fluorophenoxy) phenyl]-1-methyl-2-propenyl]-N-hydroxyurea (BW-B 70C). They were evaluated at 24 h after reperfusion for brain infarction, neurological deficit score, and the expression of 5-LOX. Furthermore, the mechanism and the anti-inflammatory potential of BW-B 70C in the regulation of nuclear factor kappa B (NF-κB) and inflammatory inducible nitric oxide synthase (iNOS) were investigated both in vivo and in vitro. RESULTS AND DISCUSSION: Both pre- and post-treatment with BW-B 70C reduced infarctions and improved neurological deficit scores. Immunohistochemical study of brain sections showed IR-mediated increased expression of 5-LOX in the neurons and microglia. BW-B 70C down-regulated 5-LOX and inhibited iNOS expression by preventing NF-κB activation. Two other structurally different 5-LOX inhibitors were also administered post IR: caffeic acid and 2, 3, 5-trimethyl-6- [12-hydroxy-5, 10-dodecadiynyl]-1, 4-benzoquinone (AA-861). As with BW-B 70C, they provided remarkable neuroprotection. Furthermore, in vitro, BW-B 70C inhibited lipopolysaccharide (LPS) mediated nitric oxide production, iNOS induction and NF-κB activation in the BV2 microglial cell line. Treating rat primary microglia with BW-B70C confirmed blockage of LPS-mediated translocation of the p65 subunit of NF-κB from cytosol to nucleus. CONCLUSION: The study demonstrates the neuroprotective potential of 5-LOX inhibition through down-regulation of NF-κB in a rat model of experimental stroke.
format Text
id pubmed-1526713
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15267132006-08-04 Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia Jatana, Manu Giri, Shailendra Ansari, Mubeen A Elango, Chinnasamy Singh, Avtar K Singh, Inderjit Khan, Mushfiquddin J Neuroinflammation Research BACKGROUND: Stroke is one of the leading causes of death worldwide and a major cause of morbidity and mortality in the United States of America. Brain ischemia-reperfusion (IR) triggers a complex series of biochemical events including inflammation. Leukotrienes derived from 5-lipoxygenase (5-LOX) cause inflammation and are thus involved in the pathobiology of stroke injury. METHODS: To test the neuroprotective efficacy of 5-LOX inhibition in a rat model of focal cerebral IR, ischemic animals were either pre- or post-treated with a potent selective 5-LOX inhibitor, (N- [3-[3-(-fluorophenoxy) phenyl]-1-methyl-2-propenyl]-N-hydroxyurea (BW-B 70C). They were evaluated at 24 h after reperfusion for brain infarction, neurological deficit score, and the expression of 5-LOX. Furthermore, the mechanism and the anti-inflammatory potential of BW-B 70C in the regulation of nuclear factor kappa B (NF-κB) and inflammatory inducible nitric oxide synthase (iNOS) were investigated both in vivo and in vitro. RESULTS AND DISCUSSION: Both pre- and post-treatment with BW-B 70C reduced infarctions and improved neurological deficit scores. Immunohistochemical study of brain sections showed IR-mediated increased expression of 5-LOX in the neurons and microglia. BW-B 70C down-regulated 5-LOX and inhibited iNOS expression by preventing NF-κB activation. Two other structurally different 5-LOX inhibitors were also administered post IR: caffeic acid and 2, 3, 5-trimethyl-6- [12-hydroxy-5, 10-dodecadiynyl]-1, 4-benzoquinone (AA-861). As with BW-B 70C, they provided remarkable neuroprotection. Furthermore, in vitro, BW-B 70C inhibited lipopolysaccharide (LPS) mediated nitric oxide production, iNOS induction and NF-κB activation in the BV2 microglial cell line. Treating rat primary microglia with BW-B70C confirmed blockage of LPS-mediated translocation of the p65 subunit of NF-κB from cytosol to nucleus. CONCLUSION: The study demonstrates the neuroprotective potential of 5-LOX inhibition through down-regulation of NF-κB in a rat model of experimental stroke. BioMed Central 2006-05-11 /pmc/articles/PMC1526713/ /pubmed/16689995 http://dx.doi.org/10.1186/1742-2094-3-12 Text en Copyright © 2006 Jatana et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jatana, Manu
Giri, Shailendra
Ansari, Mubeen A
Elango, Chinnasamy
Singh, Avtar K
Singh, Inderjit
Khan, Mushfiquddin
Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title_full Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title_fullStr Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title_full_unstemmed Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title_short Inhibition of NF-κB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
title_sort inhibition of nf-κb activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526713/
https://www.ncbi.nlm.nih.gov/pubmed/16689995
http://dx.doi.org/10.1186/1742-2094-3-12
work_keys_str_mv AT jatanamanu inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT girishailendra inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT ansarimubeena inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT elangochinnasamy inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT singhavtark inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT singhinderjit inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia
AT khanmushfiquddin inhibitionofnfkbactivationby5lipoxygenaseinhibitorsprotectsbrainagainstinjuryinaratmodeloffocalcerebralischemia